Home › Liver Cancer (Hepatocellular Carcinoma) › NCT07265271

Project for Multi-Omics-Based Early Detection of Hepatocellular Carcinoma (PROMETHEA Study)

Who can join

Ages 18 and older · All sexes · Healthy volunteers welcome

Inclusion Criteria:

* Adults aged 18 to 100 years.
* A histologically confirmed diagnosis of hepatocellular carcinoma.
* A clinically diagnosed as chronic liver disease, including chronic hepatitis or liver cirrhosis, without evidence of hepatocellular carcinoma.
* Healthy volunteers without known liver disease or malignancy.
* Received standard diagnostic and staging procedures as per local guidelines
* Availability of blood or other biospecimens.
* Ability to provide written informed consent.

Exclusion Criteria:

* Lack of or inability to provide informed consent
* History of other active malignancies within the past 5 years
* Previous liver transplantation
* Severe systemic infection or inflammatory disease at the time of enrollment
* Inadequate sample quality or quantity

About the study

Hepatocellular carcinoma (HCC) is often diagnosed at an advanced stage, and early detection is critical for improving patient outcomes. Despite this, reliable non-invasive biomarkers for early-stage HCC are limited.

This study seeks to develop a multi-omics-based liquid biopsy assay, especially focusing on ncRNAs (e.g. tsRNA, miRNA, circRNA, lncRNA, etc.) for accurate detection of early-stage HCC.

What is being tested

• Small RNA sequence (diagnostic test)
• Rt-qPCR (diagnostic test)
• Rt-qPCR (diagnostic test)

Sponsor: City of Hope Medical Center · Participants: 600 · Started: Jan 15, 2025

Contact the study team

• Goel Ajay, PhD · Phone: 626-218-3452

Official record on ClinicalTrials.gov — NCT07265271

Locations in the U.S.

Conditions

• Liver Cancer (Hepatocellular Carcinoma)
• Liver Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.